Dosing is complete in the first cohort of the phase 1/2 clinical trial of OPGx-LCA5 for the treatment of Leber congenital amaurosis, according to a press release from Opus Genetics.An adeno-associated virus 8 vector is used to deliver a functional LCA5…
Empowering the Future of Optometry: Axcel Learning Partners with KMK Optometry to Redefine Board Exam Preparation
SAN FRANCISCO & OMAHA, Neb.–(BUSINESS WIRE)–Axcel Learning (Axcel), a professional education business backed by Alpine Investors (Alpine), today announced a new partnership with KMK Optometry (KMK), the premier provider of comprehensive optometry boa…
Aurion Biotech Announces First Canadian Subject Dosed in Phase 1 / 2 Clinical Trial
SEATTLE & CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it has dosed the first Canadian subject in its Phase 1 / 2 c…
Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases
TEL AVIV, Israel–(BUSINESS WIRE)–Azura Ophthalmics Ltd. announced multiple presentations highlighting positive efficacy and safety data from Phase 2 studies of AZR-MD-001.
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the cli…
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the pricing o…